Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PLK1 | P53350 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12893245 | 0.87 | ALDH1A1 (0.51) | MAPTRAB9AHPGDGAAKMT2A | |
| SCHEMBL17479554 | 0.87 | MAPT (0.52) | MAPTRAB9AHPGDL3MBTL1NPSR1 | |
| SCHEMBL12893239 | 0.84 | HPGD (0.68) | HPGDKMT2ASMN1; SMN2TSHRHTT | |
| SCHEMBL10095152 | 0.84 | HSD17B10 (0.56) | HPGDKMT2ASMN1; SMN2TSHRHTT | |
| SCHEMBL19899450 | 0.82 | SMN1; SMN2 (0.46) | MAPTRAB9AHPGDSMN1; SMN2NPC1 | |
| SCHEMBL13167099 | 0.79 | KMT2A (0.53) | MAPTRAB9AL3MBTL1GAAKMT2A | |
| SCHEMBL10045877 | 0.79 | SMN1; SMN2 (0.43) | MAPTRAB9AHPGDL3MBTL1SMN1; SMN2 | |
| SCHEMBL28668806 | 0.79 | MAPT (0.52) | MAPTRAB9AHPGDL3MBTL1NPSR1 | |
| SCHEMBL28805020 | 0.79 | MAPT (0.52) | MAPTRAB9AHPGDL3MBTL1NPSR1 | |
| SCHEMBL15697698 | 0.79 | ELANE (0.68) | GAAKMT2ANPC1STSCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3795563-B1 | INDOLINE ANALOGS AND USES THEREOF | ONCTERNAL THERAPEUTICS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-3795563-A1 | INDOLINE ANALOGS AND USES THEREOF | Oncternal Therapeutics, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| US-10711008-B2 | Indoline analogs and uses thereof | Oncternal Therapeutics, Inc. (US) | 2020-07-14 | — | — | US | disclosed |
| EP-3436434-B1 | INDOLINE ANALOGS AND USES THEREOF | ONCTERNAL THERAPEUTICS INC (US) | 2020-07-08 | — | — | EP | disclosed |
| US-20190337951-A1 | INDOLINE ANALOGS AND USES THEREOF | GEORGETOWN UNIVERSITY | 2019-11-07 | — | — | US | disclosed |
| US-10351569-B2 | Indoline analogs and uses thereof | Oncternal Therapeutics, Inc. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20170349600-A1 | INDOLINE ANALOGS AND USES THEREOF | GEORGETOWN UNIVERSITY | 2017-12-07 | — | — | US | disclosed |
| US-20170349600-A1 | INDOLINE ANALOGS AND USES THEREOF | GEORGETOWN UNIVERSITY | 2017-12-07 | — | — | US | disclosed |
| US-9822122-B2 | Indoline analogs and uses thereof | Oncternal Therapeutics, Inc. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9822122-B2 | Indoline analogs and uses thereof | Oncternal Therapeutics, Inc. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20150247078-A1 | UV-CURABLE SILICONE RELEASE COMPOSITIONS | 3M INNOVATIVE PROPERTIES COMPANY | 2015-09-03 | — | — | US | disclosed |
| WO-2014074336-A1 | UV-CURABLE SILICONE ADHESIVE COMPOSITIONS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-05-15 | — | — | WO | disclosed |
| WO-2014074372-A1 | UV-CURABLE SILICONE RELEASE COMPOSITIONS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-05-15 | — | — | WO | disclosed |
| US-20090306039-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2009-12-10 | — | — | US | disclosed |
| US-20090306039-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2009-12-10 | — | — | US | disclosed |
| US-20090306039-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2009-12-10 | — | — | US | disclosed |
| CN-101490010-A | Compounds and compositions as ITPKB inhibitors | IRM LLC (VG) | 2009-07-22 | — | — | CN | disclosed |
| EP-2057124-A2 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM, LLC (BM) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008011611-A2 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008011611-A2 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337951-A1 | INDOLINE ANALOGS AND USES THEREOF | FLI1, EWSR1, IKZF1 | MAPT 2778/4885RAB9A 3508/4885HPGD 3906/4885 |
| US-10711008-B2 | Indoline analogs and uses thereof | FLI1, EWSR1, IKZF1 | MAPT 2778/4885RAB9A 3508/4885HPGD 3906/4885 |
| US-10351569-B2 | Indoline analogs and uses thereof | FLI1, EWSR1, IKZF1 | MAPT 2778/4885RAB9A 3508/4885HPGD 3906/4885 |
| US-20090306039-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IP6K1, IP6K2, IP6K3 | MAPT 3880/4885RAB9A 781/4885HPGD 3499/4885 |
| US-20170349600-A1 | INDOLINE ANALOGS AND USES THEREOF | FLI1, EWSR1, IKZF1 | MAPT 2778/4885RAB9A 3508/4885HPGD 3906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.